Lymphoma Tumor Homograft Models
Lymphomas comprise a number of diseases with different histopathological features. In recent years the main molecular drivers for the various lymphoma subtypes have been identified, leading to the identification of potential targets for therapeutic applications. To progress novel agents targeting lymphoma, relevant preclinical models are required. Our lymphoma tumor homografts have been developed by trasplantation of GEMM tumors into syngeneic hosts, preserving original tumor histo- and molecular pathology and driver mutations, including KRAS and MYC activation or TP53 loss.